---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349936"
form_type: "8-K"
ticker: "EIKN"
cik: "0001861123"
company_name: "Eikon Therapeutics, Inc."
filed_at: "2026-08-14T00:44:35+00:00"
generated_at: "2026-08-14T10:11:00.445189+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Eikon Therapeutics updates Q3 2026 corporate presentation; details not disclosed in filing

## Summary
- Eikon Therapeutics (EIKN) furnished an updated Q3 2026 corporate presentation on August 13, 2026.
- Exhibit 99.1 content is truncated in the filing; no financial, pipeline, or operational specifics are available.
- CFO Alfred Bowie, Ph.D. signed the current report; no other material events are disclosed.

## SEC filing metadata
- accession: 0001193125-26-349936
- form_type: 8-K
- ticker: EIKN
- cik: 0001861123
- company_name: Eikon Therapeutics, Inc.
- filed_at: 2026-08-14T00:44:35+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/0001193125-26-349936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861123/000119312526349936/eikn-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349936
- JSON: https://secwatch.observer/filing/0001193125-26-349936.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.